Evidence map›Paper›PMID 40374673›Full record

ArticleScientific reports2025

Machine learning for grading prediction and survival analysis in high grade glioma.

Xiangzhi Li, Xueqi Huang, Yi Shen, Sihui Yu, Lin Zheng, Yunxiang Cai, Yang Yang, Renyuan Zhang, Lingying Zhu, Enyu Wang

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiangzhi Li *Taizhou Key Laboratory of Minimally Invasive Interventional Therapy & Artificial Intelligence, Taizhou Branch of Zhejiang Cancer Hospital (Taizhou Cancer Hospital), No.50, Zhenxin Road, Taizhou, 317502, China.
Xueqi Huang *School of Science & School of Medicine, Guangxi University of Science and Technology, Liuzhou, 545006, China.
Yi Shen *School of Public Health, Youjiang Medical University For Nationalities, Baise, 533000, China.
Sihui YuSchool of Science & School of Medicine, Guangxi University of Science and Technology, Liuzhou, 545006, China.
Lin ZhengTaizhou Key Laboratory of Minimally Invasive Interventional Therapy & Artificial Intelligence, Taizhou Branch of Zhejiang Cancer Hospital (Taizhou Cancer Hospital), No.50, Zhenxin Road, Taizhou, 317502, China.
Yunxiang CaiTaizhou Key Laboratory of Minimally Invasive Interventional Therapy & Artificial Intelligence, Taizhou Branch of Zhejiang Cancer Hospital (Taizhou Cancer Hospital), No.50, Zhenxin Road, Taizhou, 317502, China.
Yang YangDepartment of Radiation Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.
Renyuan ZhangDepartment of International Education College, Hainan Medical University, Haikou, 571199, China.
Lingying ZhuTaizhou Key Laboratory of Minimally Invasive Interventional Therapy & Artificial Intelligence, Taizhou Branch of Zhejiang Cancer Hospital (Taizhou Cancer Hospital), No.50, Zhenxin Road, Taizhou, 317502, China. whitemouse811@hotmail.com.
Enyu WangTaizhou Key Laboratory of Minimally Invasive Interventional Therapy & Artificial Intelligence, Taizhou Branch of Zhejiang Cancer Hospital (Taizhou Cancer Hospital), No.50, Zhenxin Road, Taizhou, 317502, China. fishman811@sohu.com.

Funding

Science and Technology Plan Projects of Liuzhou 2022CAC0229Science and Technology Program of Traditional Chinese Medicine of Zhejiang Province 2024ZL1261Taizhou Social Development Science and Technology Program No. 23yvb138 and No. 23yvb140Wenling Social Development Science and Technology Program No.2021S00042, No.2021S00088 and No.2023S00011Zhejiang Provincial Science and Technology Program for Medicine and Health No. 2025KY1898Zhejiang Science and Technology Plan for Disease Prevention and Control 2025JK137
6 · The paper itself

Abstract

We developed and validated a magnetic resonance imaging (MRI)-based radiomics model for the classification of high-grade glioma (HGG) and determined the optimal machine learning (ML) approach. This retrospective analysis included 184 patients (59 grade III lesions and 125 grade IV lesions). Radiomics features were extracted from MRI with T1-weighted imaging (T1WI). The least absolute shrinkage and selection operator (LASSO) feature selection method and seven classification methods including logistic regression, XGBoost, Decision Tree, Random Forest (RF), Adaboost, Gradient Boosting Decision Tree, and Stacking fusion model were used to differentiate HGG. Performance was compared on AUC, sensitivity, accuracy, precision and specificity. In the non-fusion models, the best performance was achieved by using the XGBoost classifier, and using SMOTE to deal with the data imbalance to improve the performance of all the classifiers. The Stacking fusion model performed the best, with an AUC = 0.95 (sensitivity of 0.84; accuracy of 0.85; F1 score of 0.85). MRI-based quantitative radiomics features have good performance in identifying the classification of HGG. The XGBoost method outperforms the classifiers in the non-fusion model and the Stacking fusion model outperforms the non-fusion model.

Indexed as

Brain NeoplasmsGliomaMachine LearningAdultAgedFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedNeoplasm GradingRetrospective StudiesSurvival AnalysisCerebral glioblastomaMachine learningMagnetic resonance imagingRadiomics analysis

Identifiers

PMID40374673
PMCPMC12081730

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.